首页 > 最新文献

Annals of Oncology最新文献

英文 中文
The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors 东西方联合放射治疗神经内分泌肿瘤的疗效。
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.09.015
R.P. Riechelmann , R. Garcia-Carbonero
{"title":"The East and West consolidated efficacy of radioligand therapy in neuroendocrine tumors","authors":"R.P. Riechelmann , R. Garcia-Carbonero","doi":"10.1016/j.annonc.2025.09.015","DOIUrl":"10.1016/j.annonc.2025.09.015","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 12","pages":"Pages 1427-1430"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145328060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer 根据癌症风险和患者偏好定制治疗：2025年圣加仑国际乳腺癌共识声明：早期乳腺癌患者个体化治疗
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.09.007
H.J. Burstein , G. Curigliano , M. Gnant , S. Loibl , M.M. Regan , S. Loi , C. Denkert , P. Poortmans , D. Cameron , B. Thurlimann , W.P. Weber

Background

Breast cancer is a global disease affecting millions of individuals. Ongoing advancements in multidisciplinary management of breast cancer patients warrant discussion and integration into standard treatment plans.

Design

The St Gallen Breast Cancer Consensus conference is an international, biennial meeting where experts make treatment recommendations for state-of-the-art care of early stage breast cancer.

Results

Important innovations in the 2025 St Gallen recommendations include updated guidance on genetic testing; endorsement of hypofractionated, and ultra-hypofractionated, radiation therapy schedules for larger numbers of patients; recommendation for platinum-based chemotherapy in triple-negative breast cancer, and use of biological risk markers to consider anthracyclines in other breast cancer subtypes; avoidance of sentinel lymph node surgery in many patients with low-risk, estrogen receptor (ER)-positive cancers; use of immunotherapy in triple-negative and certain ER low-positive tumors; guidance for re-irradiation and systemic therapy in the setting of local-regional recurrence; criteria to guide treatment of oligometastatic breast cancer; and important recommendations for improving survivorship by minimizing neuropathy symptoms and addressing sexual health concerns of breast cancer patients.

Conclusions

International, multidisciplinary guidance for early breast cancer is evolving and offers patients better outcomes, improved treatment choices, and greater concern for patient preferences and survivorship needs.
背景：乳腺癌是一种影响数百万人的全球性疾病。乳腺癌患者多学科管理的持续进步值得讨论并纳入标准治疗计划。设计：圣加仑乳腺癌共识会议是一个两年一次的国际会议，专家们为早期乳腺癌提供最先进的治疗建议。结果：2025年圣加仑建议的重要创新包括更新了基因检测指南；对大量患者的低分割和超分割放射治疗方案的认可；推荐三阴性乳腺癌采用铂类化疗，并使用生物风险标志物考虑蒽环类药物治疗其他乳腺癌亚型；许多低风险ER阳性癌症患者避免前哨淋巴结手术；免疫治疗在三阴性和某些低er阳性肿瘤中的应用；局部复发的再照射和全身治疗指南；指导低转移性乳腺癌治疗的标准以及通过减少神经病变症状和解决乳腺癌患者的性健康问题来提高生存率的重要建议。结论：早期乳腺癌的国际多学科指导正在发展，为患者提供了更好的结果，改进了治疗选择，并更关注患者的偏好和生存需求。
{"title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","authors":"H.J. Burstein ,&nbsp;G. Curigliano ,&nbsp;M. Gnant ,&nbsp;S. Loibl ,&nbsp;M.M. Regan ,&nbsp;S. Loi ,&nbsp;C. Denkert ,&nbsp;P. Poortmans ,&nbsp;D. Cameron ,&nbsp;B. Thurlimann ,&nbsp;W.P. Weber","doi":"10.1016/j.annonc.2025.09.007","DOIUrl":"10.1016/j.annonc.2025.09.007","url":null,"abstract":"<div><h3>Background</h3><div>Breast cancer is a global disease affecting millions of individuals. Ongoing advancements in multidisciplinary management of breast cancer patients warrant discussion and integration into standard treatment plans.</div></div><div><h3>Design</h3><div>The St Gallen Breast Cancer Consensus conference is an international, biennial meeting where experts make treatment recommendations for state-of-the-art care of early stage breast cancer.</div></div><div><h3>Results</h3><div>Important innovations in the 2025 St Gallen recommendations include updated guidance on genetic testing; endorsement of hypofractionated, and ultra-hypofractionated, radiation therapy schedules for larger numbers of patients; recommendation for platinum-based chemotherapy in triple-negative breast cancer, and use of biological risk markers to consider anthracyclines in other breast cancer subtypes; avoidance of sentinel lymph node surgery in many patients with low-risk, estrogen receptor (ER)-positive cancers; use of immunotherapy in triple-negative and certain ER low-positive tumors; guidance for re-irradiation and systemic therapy in the setting of local-regional recurrence; criteria to guide treatment of oligometastatic breast cancer; and important recommendations for improving survivorship by minimizing neuropathy symptoms and addressing sexual health concerns of breast cancer patients.</div></div><div><h3>Conclusions</h3><div>International, multidisciplinary guidance for early breast cancer is evolving and offers patients better outcomes, improved treatment choices, and greater concern for patient preferences and survivorship needs.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 12","pages":"Pages 1433-1446"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145273563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition 靶向表观基因组和免疫逃避：PRMT5抑制的新篇章。
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.09.014
P.A. Shah, J. Rodon
{"title":"Targeting the epigenome and immune evasion: a new chapter in PRMT5 inhibition","authors":"P.A. Shah,&nbsp;J. Rodon","doi":"10.1016/j.annonc.2025.09.014","DOIUrl":"10.1016/j.annonc.2025.09.014","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 12","pages":"Pages 1431-1432"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145443711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
86MO Minimal important differences in the EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: Results from a randomized trial 日本人群中转移性乳腺癌患者的EORTC QLQ-C30和QLQ-BR23的微小重要差异：来自一项随机试验的结果
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.921
Y. Aoyama , K. Kashiwabara , Y. Kikawa , N. Taira , H. Mukai , M. Takahashi
{"title":"86MO Minimal important differences in the EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: Results from a randomized trial","authors":"Y. Aoyama ,&nbsp;K. Kashiwabara ,&nbsp;Y. Kikawa ,&nbsp;N. Taira ,&nbsp;H. Mukai ,&nbsp;M. Takahashi","doi":"10.1016/j.annonc.2025.10.921","DOIUrl":"10.1016/j.annonc.2025.10.921","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1787"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
45eP Comparison the clinical efficacy and safety of AT regimen and AT-NP regimen in the neoadjuvant treatment of HER2-negative breast cancer 45eP比较AT方案与AT- np方案在her2阴性乳腺癌新辅助治疗中的临床疗效和安全性
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.879
X. Dong , H. Song , Z. Jiang , S. Zhang
{"title":"45eP Comparison the clinical efficacy and safety of AT regimen and AT-NP regimen in the neoadjuvant treatment of HER2-negative breast cancer","authors":"X. Dong ,&nbsp;H. Song ,&nbsp;Z. Jiang ,&nbsp;S. Zhang","doi":"10.1016/j.annonc.2025.10.879","DOIUrl":"10.1016/j.annonc.2025.10.879","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1778"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
107P Efficacy of cyclic kinase 4/6 inhibitor plus endocrine therapy based on line of therapy in advanced breast cancer: A reconstructed individual participant data meta-analysis 环激酶4/6抑制剂联合内分泌治疗对晚期乳腺癌的疗效：重建个体参与者数据荟萃分析
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.942
A. Fahaid , R.H. Shembesh , M.S. Beshr , M. Elsheshtawi , M. Elhadi
{"title":"107P Efficacy of cyclic kinase 4/6 inhibitor plus endocrine therapy based on line of therapy in advanced breast cancer: A reconstructed individual participant data meta-analysis","authors":"A. Fahaid ,&nbsp;R.H. Shembesh ,&nbsp;M.S. Beshr ,&nbsp;M. Elsheshtawi ,&nbsp;M. Elhadi","doi":"10.1016/j.annonc.2025.10.942","DOIUrl":"10.1016/j.annonc.2025.10.942","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1793"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145801945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
115P Trop-2 high, stronger response: A meta-analysis of ADC efficacy in metastatic triple-negative breast cancer 115P Trop-2高，反应更强：ADC治疗转移性三阴性乳腺癌疗效的荟萃分析
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.950
M.A.W. Hutapea , S. Chen , A. Kurniawan
{"title":"115P Trop-2 high, stronger response: A meta-analysis of ADC efficacy in metastatic triple-negative breast cancer","authors":"M.A.W. Hutapea ,&nbsp;S. Chen ,&nbsp;A. Kurniawan","doi":"10.1016/j.annonc.2025.10.950","DOIUrl":"10.1016/j.annonc.2025.10.950","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1795"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
15P Utilization of neoadjuvant therapy for stage II-III HER2-positive breast cancer in Vietnam: A 10-year analysis on 2390 patients 越南II-III期her2阳性乳腺癌新辅助治疗的应用：2390例患者的10年分析
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.849
P.N. Huyen, H.T. Phung Thi, T. Nguyen, Q.H. Nguyen, H. Le, T.H. Nguyen, T.G. Dang, H.C. Khuc Chi, L.T. Nguyen
{"title":"15P Utilization of neoadjuvant therapy for stage II-III HER2-positive breast cancer in Vietnam: A 10-year analysis on 2390 patients","authors":"P.N. Huyen,&nbsp;H.T. Phung Thi,&nbsp;T. Nguyen,&nbsp;Q.H. Nguyen,&nbsp;H. Le,&nbsp;T.H. Nguyen,&nbsp;T.G. Dang,&nbsp;H.C. Khuc Chi,&nbsp;L.T. Nguyen","doi":"10.1016/j.annonc.2025.10.849","DOIUrl":"10.1016/j.annonc.2025.10.849","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Pages S1769-S1770"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
56eP Early detection, better protection: Women's knowledge, attitude and practice of breast cancer screening in Kesiman, Denpasar, Bali 早期发现，更好的保护：巴厘岛登巴萨Kesiman地区妇女乳腺癌筛查的知识、态度和实践
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.890
I.G.N.M. Wirajangsa , S.A. Arta Suryantari , A.A. Intan Pramesti
{"title":"56eP Early detection, better protection: Women's knowledge, attitude and practice of breast cancer screening in Kesiman, Denpasar, Bali","authors":"I.G.N.M. Wirajangsa ,&nbsp;S.A. Arta Suryantari ,&nbsp;A.A. Intan Pramesti","doi":"10.1016/j.annonc.2025.10.890","DOIUrl":"10.1016/j.annonc.2025.10.890","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1780"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
30P Identification of a potential subgroup of breast cancer patients with cN0–ycN0 status in whom sentinel lymph node biopsy may be omitted 30P确定cN0-ycN0状态的乳腺癌患者的潜在亚组，其中前哨淋巴结活检可能被省略
IF 65.4 1区 医学 Q1 ONCOLOGY
Annals of Oncology
Pub Date : 2025-12-01 DOI: 10.1016/j.annonc.2025.10.864
G. Khakimova , G. Khakimov
{"title":"30P Identification of a potential subgroup of breast cancer patients with cN0–ycN0 status in whom sentinel lymph node biopsy may be omitted","authors":"G. Khakimova ,&nbsp;G. Khakimov","doi":"10.1016/j.annonc.2025.10.864","DOIUrl":"10.1016/j.annonc.2025.10.864","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S1773"},"PeriodicalIF":65.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145802185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Annals of Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1